SCHEMBL21977983

SCHEMBL21977983

CC(C)(O)CNc1cc(Nc2ccnc(C(C)(F)F)c2)nc(-c2cccc(O)c2)n1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IDH2 P48735 11/20 0.49
▸ IDH1 O75874 8/20 0.48
▸ ABCB11 O95342 1/20 0.48
▸ ADORA3 P0DMS8 1/20 0.48
▸ CHRM1 P11229 1/20 0.48
▸ TBXA2R P21731 1/20 0.48
▸ PTGS1 P23219 1/20 0.48
▸ ADORA1 P30542 1/20 0.48
▸ ADRA1A P35348 1/20 0.48
▸ OPRM1 P35372 1/20 0.48
▸ KDR P35968 1/20 0.48
▸ KCNH2 Q12809 1/20 0.48
▸ SYK P43405 2/20 0.42
▸ ABCG2 Q9UNQ0 2/20 0.42
▸ ABCB1 P08183 1/20 0.39
▸ ABCC1 P33527 1/20 0.39
▸ FPR2 P25090 1/20 0.38
▸ SCN9A Q15858 1/20 0.38
▸ TGFBR1 P36897 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16392103 0.94 IDH2 (0.56) IDH2IDH1ABCB11ADORA3CHRM1
SCHEMBL21980586 0.84 IDH1 (0.48) IDH2IDH1SYKABCG2ABCB1
SCHEMBL16392148 0.84 IDH1 (0.64) IDH2IDH1ABCB11ADORA3CHRM1
SCHEMBL16392228 0.83 IDH1 (0.70) IDH2IDH1ABCB11ADORA3CHRM1
SCHEMBL15102508 0.81 IDH2 (0.73) IDH2IDH1ABCB11ADORA3CHRM1
SCHEMBL16391748 0.81 IDH2 (0.70) IDH2IDH1ABCB11ADORA3CHRM1
SCHEMBL16391840 0.78 IDH1 (0.75) IDH2IDH1ABCB11ADORA3CHRM1
SCHEMBL16392252 0.77 IDH1 (0.51) IDH2IDH1ABCB11ADORA3CHRM1
SCHEMBL16392124 0.77 IDH2 (0.58) IDH2IDH1ABCB11ADORA3CHRM1
SCHEMBL16392109 0.76 IDH1 (0.64) IDH2IDH1ABCB11ADORA3CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3019480-B1 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS INC (US) 2020-05-06 — — EP disclosed
Send feedback